-$1.27 EPS Expected for UroGen Pharma Ltd. (NASDAQ:URGN) This Quarter

Brokerages expect UroGen Pharma Ltd. (NASDAQ:URGN) to post earnings of ($1.27) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for UroGen Pharma’s earnings. The lowest EPS estimate is ($1.39) and the highest is ($1.08). UroGen Pharma reported earnings per share of ($1.38) during the same quarter last year, which suggests a positive year-over-year growth rate of 8%. The firm is expected to report its next earnings report on Thursday, March 17th.

On average, analysts expect that UroGen Pharma will report full-year earnings of ($4.86) per share for the current year, with EPS estimates ranging from ($5.08) to ($4.69). For the next year, analysts expect that the business will report earnings of ($3.33) per share, with EPS estimates ranging from ($4.28) to ($2.48). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow UroGen Pharma.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Monday, November 15th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.09). UroGen Pharma had a negative net margin of 349.05% and a negative return on equity of 127.56%. During the same period in the previous year, the business posted ($1.31) EPS.

Separately, Zacks Investment Research raised UroGen Pharma from a “sell” rating to a “hold” rating in a research report on Friday, November 19th.

Several institutional investors and hedge funds have recently bought and sold shares of URGN. BlackRock Inc. raised its position in UroGen Pharma by 3.4% in the 2nd quarter. BlackRock Inc. now owns 1,727,039 shares of the company’s stock worth $26,372,000 after buying an additional 56,434 shares during the last quarter. RTW Investments LP purchased a new position in UroGen Pharma in the 3rd quarter worth about $14,423,000. Great Point Partners LLC purchased a new position in UroGen Pharma in the 3rd quarter worth about $12,615,000. Zeke Capital Advisors LLC raised its position in UroGen Pharma by 39.8% in the 2nd quarter. Zeke Capital Advisors LLC now owns 722,875 shares of the company’s stock worth $11,038,000 after buying an additional 205,769 shares during the last quarter. Finally, Horton Capital Management LLC raised its position in UroGen Pharma by 9.0% in the 3rd quarter. Horton Capital Management LLC now owns 684,749 shares of the company’s stock worth $11,517,000 after buying an additional 56,674 shares during the last quarter.

Shares of URGN traded up $0.72 during trading hours on Thursday, hitting $12.76. The company had a trading volume of 95,608 shares, compared to its average volume of 146,389. The firm has a fifty day moving average price of $16.48 and a 200-day moving average price of $16.39. The stock has a market capitalization of $266.68 million, a price-to-earnings ratio of -2.54 and a beta of 1.18. UroGen Pharma has a 52-week low of $11.67 and a 52-week high of $28.20.

UroGen Pharma Company Profile

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. It has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.

Recommended Story: Portfolio Manager

Get a free copy of the Zacks research report on UroGen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for UroGen Pharma (NASDAQ:URGN)

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.